Investigating Immune Checkpoint Inhibitor-Induced Pancreatic Injury: When to Discontinue Cancer Therapy

Investigating Immune Checkpoint Inhibitor-Induced Pancreatic Injury: When to Discontinue Cancer Therapy

<b>Background/Objectives:</b> The increasing use of immune checkpoint inhibitors (ICIs) in cancer treatment has led to a rise in immune-related adverse events (irAEs), including pancreatic injury. While current guidelines suggest that baseline monitoring of amylase and lipase levels is n...

Full description

Saved in:
Bibliographic Details
Main Authors: Enrico Celestino Nista, Sara Sofia De Lucia, Sebastiano Archilei, Jacopo Iaccarino, Giulia Piccirilli, Alberto Nicoletti, Angela Saviano, Antonio Gasbarrini, Veronica Ojetti
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Metabolites
Subjects:
immune checkpoint inhibitors
immune-related adverse events
metabolic perturbations
pancreatic injury
Online Access:https://www.mdpi.com/2218-1989/15/6/385
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.mdpi.com/2218-1989/15/6/385

Similar Items